Loading...
Docoh
Log in Free sign up

Zynex (ZYXI)

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers.

Company profile

Ticker
ZYXI
Exchange
NASDAQ
Website
www.zynex.com
CEO
Thomas Sandgaard
Employees
Incorporated
Nevada
Location
Colorado
Fiscal year end
Dec 31
Sector
Manufacturing > Surgical and Medical Instrument Manufacturing
Industry (SIC)
Electromedical & Electrotherapeutic Apparatus
Medtronic • Varian Medical Systems • Conmed • Masimo • Natus Medical • LivaNova • Outset Medical • Fonar • Cutera • Inmode ...
Former names
ARIZONA VENTURES INC, CHINA GLOBAL DEVELOPMENT INC, FOX RIVER HOLDINGS INC, IBONZAI COM INC, LIFE MEDICAL TECHNOLOGIES INC /UT/, ZYNEX MEDICAL HOLDINGS INC, ZYNEX MEDICAL HOLDINGS INC
SEC CIK
0000846475
Corporate docs
Subsidiaries
Zynex Medical, Inc. • Zynex Monitoring Solutions, Inc. • Zynex NeuroDiagnostics, Inc. • Zynex Europe, ApS • Pharmazy, Inc • Kestrel Labs, Inc. ...
IRS number
870403828

ZYXI stock data

News

From Benzinga Pro
Zynex Earnings Perspective: Return On Capital Employed
5 Aug 22
According to Benzinga Pro, during Q2, Zynex (NASDAQ:ZYXI) earned $3.35 million, a 142.99% increase from the preceding quarter. Zynex also posted a total of $36.76 million in sales, a 18.26% increase since Q1.
Zynex: Q2 Earnings Insights
28 Jul 22
Zynex (NASDAQ:ZYXI) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Zynex beat estimated earnings by 14.29%, reporting an EPS of $0.08 versus an estimate of $0.07.
Zynex Q2 EPS $0.08 Beats $0.07 Estimate, Sales $36.80M Beat $36.30M Estimate
28 Jul 22
Zynex (NASDAQ:ZYXI) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.07 by 14.29 percent. This is a 14.29 percent increase over earnings of $0.07 per share from the same
Earnings Scheduled For July 28, 2022
28 Jul 22
Earnings Preview: Zynex
27 Jul 22

Press releases

From Benzinga Pro
Zynex Recognized in Top 100 Healthcare Technology Companies of 2022
8 Aug 22
ENGLEWOOD, Colo., Aug. 8, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management,
Zynex Ranked in Top 50 Public Companies in Colorado
3 Aug 22
ENGLEWOOD, Colo., Aug. 3, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management,
Zynex Announces 2022 Second Quarter Earnings
28 Jul 22
ENGLEWOOD, Colo., July 28, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management,
Zynex, Inc. to Announce Second Quarter 2022 Financial Results
20 Jul 22
Zynex Reports Preliminary Second Quarter 2022 Results and Reiterates Full Year Revenue and EBITDA Guidance
11 Jul 22

Calendar

28 Jul 22
12 Aug 22
31 Dec 22

Financial summary

Financial statements Chart ZYXI financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 26.88M 26.88M 26.88M 26.88M 26.88M 26.88M
Cash burn (monthly) 4.12M 1.31M (no burn) (no burn) 58.67K (no burn)
Cash used (since last report) 5.9M 1.88M n/a n/a 84K n/a
Cash remaining 20.97M 25M n/a n/a 26.79M n/a
Runway (months of cash) 5.1 19.1 n/a n/a 456.7 n/a

Beta Read what these cash burn values mean

Financial data from Zynex earnings reports.

Recent insider trades

ZYXI insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Aug 22 Daniel J Moorhead Common Stock Payment of exercise Dispose F No No 9.34 626 5.85K 47,693
5 Aug 22 Daniel J Moorhead Common Stock (Restricted Stock Award) Grant Acquire A No No 0 8,012 0 109,525
5 Aug 22 Anna Lucsok Common Stock Payment of exercise Dispose F No No 9.34 97 905.98 11,601
5 Aug 22 Anna Lucsok Common Stock (Restricted Stock Award) Grant Acquire A No No 0 3,205 0 89,708
5 Aug 22 Sandgaard Thomas Common Stock Payment of exercise Dispose F No No 9.34 242 2.26K 14,983,205
5 Aug 22 Sandgaard Thomas Common Stock (Restricted Stock Award) Grant Acquire A No No 0 8,012 0 21,777
29 Jul 22 Sandgaard Thomas Common Stock Payment of exercise Dispose F No No 8.58 209 1.79K 14,982,795
29 Jul 22 Daniel J Moorhead Common Stock Payment of exercise Dispose F No No 8.58 209 1.79K 46,631
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

ZYXI institutional ownership history Ownership history
5.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 128 116 +10.3%
Opened positions 29 24 +20.8%
Closed positions 17 18 -5.6%
Increased positions 81 40 +102.5%
Reduced positions 16 30 -46.7%
13F shares Current Prev Q Change
Total value 103.45M 1.16B -91.1%
Total shares 15.18M 12.35M +22.9%
Total puts 50.44K 117K -56.9%
Total calls 34.58K 125.3K -72.4%
Total put/call ratio 1.5 0.9 +56.2%
Largest owners Shares Value Change
BLK Blackrock 3.42M $21.31M +12.7%
Vanguard 1.41M $8.82M +8.0%
Sandgaard Thomas 1.3M $17.02M 0.0%
STT State Street 675.63K $4.21M +13.4%
Allspring Global Investments 572.19K $3.56M +926.6%
Millennium Management 532.87K $3.32M +39.6%
Geode Capital Management 408.73K $2.55M +16.3%
Punch & Associates Investment Management 394.8K $2.46M -5.6%
GS Goldman Sachs 360.22K $2.24M -34.0%
Citadel Advisors 355.93K $2.22M +253.0%
Largest transactions Shares Bought/sold Change
Allspring Global Investments 572.19K +516.46K +926.6%
BLK Blackrock 3.42M +384.55K +12.7%
Citadel Advisors 355.93K +255.09K +253.0%
FHI Federated Hermes 222.56K +204.73K +1148.0%
GS Goldman Sachs 360.22K -185.74K -34.0%
Oak Ridge Investments 0 -182.99K EXIT
D. E. Shaw & Co. 272.53K +151.47K +125.1%
Millennium Management 532.87K +151.24K +39.6%
MS Morgan Stanley 242.46K +144.26K +146.9%
Renaissance Technologies 192.04K +114.28K +147.0%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Management Discussion
  • Net revenue was $36.8 million and $31.0 million for the three months ended June 30, 2022 and 2021, respectively, and $67.8 million and $55.1 million for the six months ended June 30, 2022 and 2021, respectively. Net revenue increased 18% and 23% for the three and six-month periods ended June 30, 2022, respectively. Net income was $3.3 million for the three months ended June 30, 2022 compared with $2.8 million during the same period in 2021. Net income was $4.7 million for the six months ended June 30, 2022 compared with $2.1 million during the same period in 2021. Cash provided by operating activities was $1.6 million during the six months ended June 30, 2022. Working capital was $51.8 million and $59.8 million as of June 30, 2022 and December 31, 2021, respectively.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: announced, competitive, created, flat, fully, funded, HemeOxTM, inflation, instrument, job, NiCOTM, online, publicly, research, shipment, team, trade, utilitzed
Removed: attributable, September
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
28 Jul 22
10-Q
2022 Q1
Quarterly report
28 Apr 22
10-K
2021 FY
Annual report
21 Mar 22
10-Q
2021 Q3
Quarterly report
2 Nov 21
10-Q
2021 Q2
Quarterly report
29 Jul 21
10-Q
2021 Q1
Quarterly report
29 Apr 21
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
27 Oct 20
10-Q
2020 Q2
Quarterly report
28 Jul 20
10-Q
2020 Q1
Quarterly report
28 Apr 20
Current reports
View all
8-K
Zynex Announces 2022 Second Quarter Earnings
28 Jul 22
8-K
Zynex Reports Preliminary Second Quarter 2022 Results and Reiterates Full Year Revenue and EBITDA Guidance
11 Jul 22
8-K
Departure of Directors or Certain Officers
29 Jun 22
8-K
Zynex Announces Change of Auditor
13 Jun 22
8-K
Zynex Announces Additional Share Buyback Program
9 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
19 May 22
8-K
Zynex Announces 2022 First Quarter Earnings
29 Apr 22
8-K
Zynex Announces Share Buyback Program
11 Apr 22
8-K
Zynex Reports Preliminary First Quarter 2022 Results and Provides Business Update
8 Apr 22
8-K
Zynex Announces 2021 Fourth Quarter and Full Year Earnings
28 Feb 22
Registration and prospectus
View all
424B5
Prospectus supplement for primary offering
16 Jul 20
424B7
Prospectus with selling stockholder info
16 Jul 20
424B5
Prospectus supplement for primary offering
14 Jul 20
424B7
Prospectus with selling stockholder info
14 Jul 20
424B5
Prospectus supplement for primary offering
29 Oct 19
S-3
Shelf registration
26 Jun 19
S-3
Shelf registration
7 Mar 19
8-A12B
Registration of securities on exchange
7 Feb 19
S-8
Registration of securities for employees
5 Sep 17
D
$1.5M in equity / debt
24 Nov 16
Proxies
DEFA14A
Additional proxy soliciting materials
8 Apr 22
DEF 14A
Definitive proxy
1 Apr 22
DEF 14A
Definitive proxy
2 Apr 21
DEFA14A
Additional proxy soliciting materials
2 Apr 20
DEF 14A
Definitive proxy
2 Apr 20
PRE 14C
Preliminary information
26 Aug 02
Other
View all
EFFECT
Notice of effectiveness
5 Jul 19
UPLOAD
Letter from SEC
1 Jul 19
CORRESP
Correspondence with SEC
30 Jun 19
EFFECT
Notice of effectiveness
13 Mar 19
UPLOAD
Letter from SEC
10 Mar 19
CORRESP
Correspondence with SEC
7 Mar 19
CERT
Certification of approval for exchange listing
11 Feb 19
UPLOAD
Letter from SEC
28 Sep 09
CORRESP
Correspondence with SEC
17 Sep 09
UPLOAD
Letter from SEC
7 Sep 09
Ownership
View all
4
ZYNEX / Thomas Sandgaard ownership change
8 Aug 22
4
ZYNEX / DANIEL J MOORHEAD ownership change
8 Aug 22
4
ZYNEX / Anna Lucsok ownership change
8 Aug 22
4
ZYNEX / Thomas Sandgaard ownership change
29 Jul 22
4
ZYNEX / DANIEL J MOORHEAD ownership change
29 Jul 22
4
ZYNEX / Anna Lucsok ownership change
29 Jul 22
4
ZYNEX / DANIEL J MOORHEAD ownership change
8 Jul 22
4
ZYNEX / DANIEL J MOORHEAD ownership change
27 Jun 22
4
ZYNEX / Thomas Sandgaard ownership change
27 Jun 22
4
ZYNEX / Anna Lucsok ownership change
27 Jun 22

Patents

Utility
Multiparameter Noninvasive Sepsis Monitor
30 Jun 22
A system for monitoring sepsis comprises one or more sensors that noninvasively monitor a patient to produce sensor data and processing circuitry to: derive, from the sensor data, one or more physiological parameters of the patient that are indicative of a sepsis state of the patient; apply a set of rules to the one or more physiological parameters; determine a sepsis state for the patient based on the set of rules applied to the one or more physiological parameters; and output at least one signal indicative of the sepsis state of the patient.
Utility
Multiparameter Noninvasive Sepsis Monitor
30 Jun 22
A system for monitoring sepsis comprises one or more sensors that noninvasively monitor a patient to produce sensor data and processing circuitry to: derive, from the sensor data, one or more physiological parameters of the patient that are indicative of a sepsis state of the patient; apply a set of rules to the one or more physiological parameters; determine a sepsis state for the patient based on the set of rules applied to the one or more physiological parameters; and output at least one signal indicative of the sepsis state of the patient.

Transcripts

View all
2022 Q2
Earnings call transcript
29 Jul 22
2022 Q1
Earnings call transcript
29 Apr 22
2021 Q4
Earnings call transcript
25 Feb 22
2021 Q3
Earnings call transcript
3 Nov 21
2021 Q2
Earnings call transcript
30 Jul 21
2021 Q1
Earnings call transcript
30 Apr 21
2020 Q4
Earnings call transcript
26 Feb 21
2020 Q3
Earnings call transcript
27 Oct 20
2020 Q2
Earnings call transcript
28 Jul 20
2020 Q1
Earnings call transcript
28 Apr 20

Reddit threads

View all